<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874637</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-001</org_study_id>
    <nct_id>NCT03874637</nct_id>
  </id_info>
  <brief_title>FemPulse Therapy First-in-Human Experience</brief_title>
  <official_title>Evaluation of a Wearable Electrical Incontinence Device in Subjects: A Non-significant Risk Clinical Evaluation of FemPulse Therapy in Women With OAB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FemPulse Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FemPulse Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to investigate a new medical device treatment for
      Overactive Bladder (OAB) in women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FemPulse System is a vaginal ring intended to provide mild electrical stimulation to
      nerves in the lower abdomen that regulate bladder function. It is believed that stimulation
      of these nerves may help relieve the symptoms of OAB.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Actual">May 17, 2017</completion_date>
  <primary_completion_date type="Actual">May 17, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects will be treated at 2 different device settings (one of which is Off) in random sequence during two 6-hour periods at least one week apart.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>3 days in total</time_frame>
    <description>All device- and procedure-related adverse events will be collected and tabulated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Placeability and comfort of the device</measure>
    <time_frame>3 days in total</time_frame>
    <description>Subjects will be observed for their ability to place, orient and wear the device without discomfort. The outcome is Pass or Fail as determined by the investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of urinary voids</measure>
    <time_frame>3 days in total</time_frame>
    <description>The number of voids per day will be tabulated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intervals between urinary voids</measure>
    <time_frame>3 days in total</time_frame>
    <description>The time between voids (hours:minutes) will be tabulated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urge urinary incontinence (UUI)</measure>
    <time_frame>3 days in total</time_frame>
    <description>Presence or absence of UUI with each void</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Urinary Bladder, Overactive</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Treament</intervention_name>
    <description>Placement of the FemPulse System with therapy delivery</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Control</intervention_name>
    <description>Placement of the FemPulse System without therapy delivery</description>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females â‰¥21 yrs with Overactive Bladder

        Exclusion Criteria:

          -  Is or was recently pregnant

          -  Has a metal pelvic implant or any electrically active implanted medical device

          -  Has a urinary tract or vaginal infection

          -  Had a previous hysterectomy, pelvic radiation or pelvic cancer

          -  Has significant pelvic organ prolapse

          -  Had bladder treatment with onabotulinumtoxinA in the previous 12 months or Tibial
             Nerve stimulation within the previous 30 days

          -  Has a significant heart condition or a history of vasovagal reaction or low blood
             pressure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Minnesota Urology</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>March 12, 2019</last_update_submitted>
  <last_update_submitted_qc>March 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Overactive Bladder</keyword>
  <keyword>Women</keyword>
  <keyword>Neuromodulation</keyword>
  <keyword>Bioelectronic Medicine</keyword>
  <keyword>Non-significant Risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

